The emerging evidence reveals that protein arginine methyltransferase 5 (PRMT5) is involved in regulation of tumour cell proliferation and cancer development. Nevertheless, the exact role of PRMT5 in human lung cancer cell proliferation and the underlying molecular mechanism remains largely obscure. Here, we showed that PRMT5 was highly expressed in human lung cancer cells and lung cancer tissues.
variety of biological processes via different signalling axis, such as modification of histones and gene expression, chromatin reconstruction, protein modification, cell cycle progression, cell invasion, cell metabolism and development. 2 In addition to these functions, PRMT5 plays a pivotal role in regulation of cancer cell growth and transformation. It has been reported that down-regulation of PRMT5 by RNAi prevented cancer cell proliferation and cell cycle transition through PI3K/Akt signalling pathway 3 and a large number of corroborating studies have shown that PRMT5 expression level was significantly elevated in various cancers, including gastric, 4 colorectal, 5 lung, 3 lymphoma, 6 leukaemia 7 and liver 8 cancers.
However, the molecular mechanism of PRMT5 regulation of PI3K/ Akt signalling axis is completely unknown.
In this study, our results revealed that PRMT5 was overex- with 10% FBS. All cells were maintained at 37°C in a humidified atmosphere containing 5% CO 2 % and 95% air. PRMT5 specific inhibitor GSK591 (cat no. SML-1751) was purchased from Sigma.
| MATERIALS AND METHODS

| Cell culture and chemicals
Primary
| Plasmids and lentivirus preparation
Human PRMT5 and Akt shRNA knockdown lentiviral constructs were generated using pLVTHM vector, and lentivirus were generated by co-transfection along with packaging plasmid MD2G (Addgene) and helper plasmid PAX2 (Addgene) into HEK293T cells. After 48 hours, the medium was collected and viral titers were pre-determined. In all indicated experiments, the same number of viral particles was used. Human PRMT5 knockdown targeting sequences are:
shRNA-1,5'-GGATAAAGCTGTATGCTGT-3'; shRNA2: 5'-GCCATCTA- 
| Gene expression assay
Total RNA was isolated from A549 and H1299 cells or human lung cancer tissues using TRIzol reagent (Cat no. 15596-018; Invitrogen)
according to the manufacturer's recommendation, and the equal amount of RNA was subjected to reverse transcription. Quantitative real-time PCR (qRT-PCR) was performed with SYBR green fluorescent Dye (cat no. 1725272; Bio-Rad) with an ABI7800 PCR machine (Applied Biosystems), and GAPGH was used as an internal control.
Relative mRNA expression was determined by the ΔΔ−Ct method.
Primer sequences are: human PRMT5 forward: 5'-CCTGTGGAGGT-GAACACAGT-3' and revise: 5'-AGAGGATGGGAAACCATGAG-3'; GA PDH, forward: 5'-GAAGGTGAAGGTCGGAGTCAACG-3' and revise:
5'-TGCCATGGGTGGAATCATATTGG-3'.
| Cell proliferation assay
For cell proliferation assay, the A549 and H1299 cells were 
| Western blotting analysis
Proteins were extracted from A549, H1299, H322, H441 PC14 and IMR90 cells and human lung cancer tissues using lysis buffer 
| Statistical analysis
All experiments were carried out in triplicate under identical conditions and data were represented as means ± SEM Differences between two groups were analysed by unpaired two-tailed Student's t test. Difference with P < 0.05 was considered statistically significant.
| RESULTS
| PRMT5 is highly expressed in human lung cancer cells and tissues
To investigate the functions of PRMT5 in human lung cancer, we firstly examined the PRMT5 protein expression level in different human lung cancer cell lines. As shown in Figure 1A 
| Down-regulation of PRMT5 prevents lung cancer cell proliferation
To investigate whether PRMT5 is implicated in lung cancer cell proliferation, we delivered the PRMT5 and scramble shRNA into Subsequently, cell proliferation rate was measured in these PRMT5 stable knockdown cells. As shown in Figure 2G ,H, cell proliferation was dramatically blocked when PRMT5 was down-regulated both in A549 and H1299 cells during the different time points.
These results indicate that PRMT5 is involved in human lung cancer cell proliferation. Previous study has reported that PRMT5 promoted liver cancer cell growth through inhibiting BTG2 expression and the up-regulation of cyclin E1 and cyclin D1. 9 Therefore, we asked if down-regulation of PRTM5 could reduce cyclin E1 and cyclin D1 expression in lung cancer cells. As expected, cyclin E1 and cyclin D1 expression was significantly decreased both in A549 and H1299 cells when PRMT5 was knocked down ( Figure 2I-K) . These results indicate that PRMT5 regulates lung cancer cell proliferation via control of cell cycle progression.
| Inhibition of PRMT5 activity suppresses lung cancer cell proliferation
To further investigate the role of PRMT5 in lung cancer cell proliferation, we used PRTM5 specific inhibitor, GSK591, to black PRMT5 activity and cell proliferation was evaluated. We found that proliferation of A549 and H1299 cells was markedly reduced in a dose dependent manner, whereas proliferation of IMR90 cells was almost no change ( Figure 3A ,B), indicating that this inhibitor has selectivity between cancer cells and normal cells. Next, the cell cycle proteins, cyclin E1 and cyclin D1, in A549 and H1299 cells were assessed upon the treatment of GSK591. We found that cyclin E1 and cyclin D1 expression level was significantly decreased both in A549 and H1299 cells ( Figure 3C -E). Taken together, these results suggest that blocking PRMT5 activity can prevent lung cancer cell proliferation and cell cycle progression.
| PRMT5 interacts with Akt in lung cancer cells
PRMT5 plays an important role in cancer cell growth and proliferation, especially in human lung cancer cells. However, the underlying molecular mechanism is completely unknown. Previous study has reported that PRMT5 up-regulated cyclin-dependent kinase and PI3K/Akt signalling pathway. 3 Nevertheless, this study only cially in many human cancer types. 10 We wonder whether PRMT5
regulates Akt activation in human lung cancer cells. As shown in Fig- ure 5A-C, Akt phosphorylation (Thr308 and Ser473) and the Akt downstream target GSK3β phosphorylation (Ser9) was markedly decreased when PRMT5 was knocked down both in A549 and H1299 cells, but PTEN and mTOR phosphorylation (Ser2442) did not change. We also examined the effect of PRMT5 inhibitor GSK591 on the Akt activity. As shown in Figure 5D -F, Akt phosphorylation (Thr308 and Ser473) and GSK3β phosphorylation (Ser9) was significantly reduced when A549 and H1299 cells were treated with GSK591, whereas the PTEN and mTOR phosphorylation (Ser2442)
did not change, indicating that PRMT5 regulation of Akt activity seems to be independent of PTEN and mTOR. To further confirm our results, the in vitro Akt kinase assay was performed both in A549 and H1299 cells. As shown in Figure 5G ,H, the GSK3α phosphorylation (Ser21) was strikingly reduced when PRMT5 was downregulated by shRNA compared with scramble group, indicating that Akt activity was impaired and PRMT5 is required for Akt activation.
Collectively, these results demonstrate that PRMT5 promotes lung cancer cell proliferation through regulation of Akt activity, but not PTEN and mTOR signalling pathway. 
| DISCUSSION
To date, it is clear that PRMT5 is an oncoprotein and plays a pivotal role in various human cancer progressions through the regulation of different signalling cascades. However, it is still unclear whether PRMT5 interacts with Akt, another important oncoprotein in human cancers, and regulates Akt activity in human lung cancer. The findings in this study showed that PRMT5 was overexpressed in human lung cancer cells (Figure 1 ). This phenomenon was further assessed in the analysis of human lung cancer tissues, in which we detected ectopic expression level of PRMT5 in human lung cancer tissues and very low expression level of PRMT5 in adjacent lung tissues (Figure 1) . In addition, we uncovered that down-regulation of PRMT5 by shRNA or blocking PRMT5 activity by specific inhibitor markedly prevented proliferation of A549 and H1299 cells (Figures 2 and 3 ).
Our findings also revealed that PRMT5 was directly co-localized and interacted with Akt and PRMT5 regulated Akt kinase activity both in Previous study has reported that silencing PRMT5 arrested cell proliferation at G1 phase. 11 In addition, CDK4/cyclin D1 complex regulated PRMT5 kinase activity by phosphorylation of MEP50 12 and PRMT5 promoted liver cancer cell growth through inhibiting BTG2 expression and up-regulation of cyclin E1 and cyclin D1. 9 Furthermore, CDT1 was methylated and stabilized by PRMT5, which promoted cells entry into S phase. 12 Transcriptional factor E2F, a key cell cycle regulator, was involved in cell-cycle progression and led to cells entry from G1-to S-phase. 13 E2F1 was directly methylated by PRMT5 and the methylation of E2F1 by PRMT5 was required for regulating E2F1's biochemical and functional properties, 14 indicating that arginine methylation resulted in cell-cycle progression affected by E2F1. All these observations suggest that PRMT5 is essential for cell proliferation via regulation of cell cycle progression and that PRMT5 is an important upstream effector for cancer cell growth. In this study, we showed that cyclin E1 and cyclin D1 expression was significantly decreased in both A549 and H1299 cells when PRMT5 was down-regulated or blocked by GSK591 ( Figures 2I and 3C 
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